Atherosclerosis
Volume 204, Issue 2 , Pages 601-607, June 2009

Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study

  • Renate Schnabel

      Affiliations

    • The NHLBI’s Framingham Heart Study, Framingham, MA, United States
  • ,
  • Josée Dupuis

      Affiliations

    • Department of Biostatistics, Boston University, School of Public Health, Boston, MA, United States
  • ,
  • Martin G. Larson

      Affiliations

    • The NHLBI’s Framingham Heart Study, Framingham, MA, United States
    • Boston University’s Mathematics and Statistics Department, Boston, MA, United States
  • ,
  • Kathryn L. Lunetta

      Affiliations

    • Department of Biostatistics, Boston University, School of Public Health, Boston, MA, United States
  • ,
  • Sander J. Robins

      Affiliations

    • Department of Preventive Medicine, Boston University, School of Medicine, Boston, MA, United States
    • The NHLBI’s Framingham Heart Study, Framingham, MA, United States
  • ,
  • Yanyan Zhu

      Affiliations

    • Department of Biostatistics, Boston University, School of Public Health, Boston, MA, United States
  • ,
  • Jian Rong

      Affiliations

    • The NHLBI’s Framingham Heart Study, Framingham, MA, United States
  • ,
  • Xiaoyan Yin

      Affiliations

    • The NHLBI’s Framingham Heart Study, Framingham, MA, United States
  • ,
  • Heide A. Stirnadel

      Affiliations

    • Cardiovascular, Metabolic and Genetic Support, GlaxoSmithKline R&D, Harlow, UK
  • ,
  • Jeanne J. Nelson

      Affiliations

    • Cardiovascular, Metabolic and Genetic Support, GlaxoSmithKline R&D, Harlow, UK
  • ,
  • Peter W.F. Wilson

      Affiliations

    • Department of Medicine, Division of Cardiology, Emory University, School of Medicine, Harlow, UK
  • ,
  • John F. Keaney
  • ,
  • Ramachandran S. Vasan

      Affiliations

    • Evans Memorial Department of Medicine, Boston University, School of Medicine, Boston, MA, United States
    • Whitaker Cardiovascular Institute, Boston University, School of Medicine, Boston, MA, United States
    • The NHLBI’s Framingham Heart Study, Framingham, MA, United States
  • ,
  • Emelia J. Benjamin

      Affiliations

    • Evans Memorial Department of Medicine, Boston University, School of Medicine, Boston, MA, United States
    • Whitaker Cardiovascular Institute, Boston University, School of Medicine, Boston, MA, United States
    • Department of Epidemiology, Boston University, School of Public Health, Boston, MA, United States
    • The NHLBI’s Framingham Heart Study, Framingham, MA, United States
    • Corresponding Author InformationCorresponding author at: Boston University, The Framingham Heart Study, 73 Mount Wayte Avenue, Suite 2, Framingham, MA 01702-5827, United States. Tel.: +1 617 638 8968; fax: +1 508 626 1262.

Received 1 July 2008; received in revised form 15 October 2008; accepted 16 October 2008. published online 09 January 2009.

Abstract 

Objective

To conduct an investigation of clinical and genetic correlates of lipoprotein-associated phospholipase (Lp-PLA2) activity and mass in a large community-based cohort. Higher circulating Lp-PLA2 predicts cardiovascular disease risk, but sources of inter-individual variability are incompletely understood.

Methods

We conducted stepwise regression of clinical correlates of Lp-PLA2 in four Framingham Heart Study cohorts (n=8185; mean age 50±14 years, 53.8% women, 9.8% ethnic/racial minority cohort). We also conducted heritability and linkage analyses in Offspring and Generation 3 cohorts (n=6945). In Offspring cohort participants we performed association analyses (n=1535 unrelated) with 1943 common tagging SNPs in 233 inflammatory candidate genes.

Results

Sixteen clinical variables explained 57% of the variability in Lp-PLA2 activity; covariates associated with Lp-PLA2 mass were similar but only explained 27% of the variability. Multivariable-adjusted heritability estimates for Lp-PLA2 activity and mass were 41% and 25%, respectively. A linkage peak was observed for Lp-PLA2 activity (chromosome 6, LOD score 2.4). None of the SNPs achieved experiment-wide statistical significance, though 12 had q values <0.50, and hence we expect at least 50% of these associations to be true positives. The strongest multivariable-association with Lp-PLA2 activity was found for MEF2A (rs2033547; nominal p=3.20×10−4); SNP rs1051931 in PLA2G7 was nominally associated (p=1.26×10−3). The most significant association to Lp-PLA2 mass was in VEGFC (rs10520358, p=9.14×10−4).

Conclusions

Cardiovascular risk factors and genetic variation contribute to variability in Lp-PLA2 activity and mass. Our genetic association analyses need replication, which will be facilitated by web posting of our genetic association results.

Abbreviations: CVD, cardiovascular disease, HDL, high-density lipoprotein, LD, linkage disequilibrium, LDL, low-density lipoprotein, Lp-PLA2, lipoprotein-associated phospholipase A2, LOD, logarithm of the odds, SE, standard error, SNP, single nucleotide polymorphism

Keywords: Lipoprotein-associated phospholipase A2, Inflammation, Heritability, Single nucleotide polymorphism

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by NIH/NHLBI contract N01-HC-25195 and NIH grants HL64753 and HL076784 AG028321 (E.J.B.), HL70139 (R.S.V). NIH Research career award HL04334 (R.S.V.), NIH grant HG000848 (J.D.); Deutsche Forschungsgemeinschaft (German Research Foundation) Research Fellowship SCHN 1149/1-1 (RS). Portion of these analyses were conducted using the Boston University Linux Cluster for Genetic Analysis (LinGA) funded by the NIH NCRR (National Center for Research Resources) Shared Instrumentation grant (1S10RR163736-01A1).

PII: S0021-9150(08)00756-9

doi:10.1016/j.atherosclerosis.2008.10.030

Atherosclerosis
Volume 204, Issue 2 , Pages 601-607, June 2009